Jazz Pharmaceuticals Wins FDA Approval for Ziihera Regimens in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals (NASDAQ:JAZZ) has secured FDA approval for two Ziihera-containing regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma, expanding the drug into an earlier treatment setting after Phase 3 data showed improvements in progression-free and overall survival.